Instructions for
Authors
Regular manuscripts may be submitted directly
to the Editorial Office by e-mail to patents@benthamscience.org
or pri@benthamscience.org.
Online Manuscript Submission:
An online submission and tracking service via Internet
facilitates a speedy and cost-effective submission of manuscripts.
The full manuscript should be submitted online
via Bentham's Content Management System (CMS) at
www.bentham-editorial.org
(View
Instructions).
Manuscripts must be submitted by one of the authors of the
manuscript, and should not be submitted by anyone on their
behalf. The principal/corresponding author will be required
to submit a Cover Letter along with the manuscript, on behalf
of all the co-authors (if any) to confirm that the manuscript
(or any part of it) has not been published previously or is
not under consideration for publication elsewhere. Furthermore,
any illustration, structure or table that has been published
elsewhere must be reported, and copyright permission for reproduction
must be obtained. The figures from patent documents are freely
available on the databases and may not require any permission
unless stated otherwise.
For all online submissions, please provide soft copies of
all the materials (main text in MS Word or Tex/LaTeX), figures/illustrations
in TIFF, PDF or JPEG, and chemical structures drawn in ChemDraw
(CDX)/ISISDraw (TGF) as separate files, while a PDF version
of the entire manuscript must also be included, embedded with
all the figures/illustrations/tables/chemical structures etc.
It is imperative that before submission, the author(s) should
carefully proofread the files for special characters, mathematical
symbols, Greek letters, equations, tables, references and
images to ensure that they appear in proper format.
References, figures, tables, chemical structures, etc. should
be referred to in the text at the appropriate places where
they have been first discussed. Figure legends / captions
should also be provided.
A successful electronic submission of the manuscript will
be confirmed by a system-generated email acknowledgement to
the principal/corresponding author immediately. Any queries
therein should be addressed at patents@benthamscience.org
MANUSCRIPTS PUBLISHED: The journal publishes
peer-reviewed mini- and full-length review and research articles,
and drug clinical trial studies written in English. Single
Topic/Thematic Issues by invited Guest Editors are also considered
for publication.
For the submission of research articles, the author should
have already filed a patent with a leading patent authority
and it should be registered, secondly the author should not
have published any research paper on the intellectual property
of that patent.
Single Topic Issues: These special issues
are peer-reviewed and may contain invited or uninvited review/mini-review
articles or a mixture of research articles and reviews/ mini-reviews.
A Single Topic Issue Editor will offer a short perspective
and co-ordinate the solicitation of manuscripts between 3-5
(for a mini-hot topic) to 6-10 (for full-length hot topic)
from leading scientists. Authors interested in editing a single
topic issue in an emerging topic of anti-infective drug discovery
may submit their proposal at qasit@benthamscience.org
or pri@benthamscience.org
for consideration.
Patent Selections:
A separate section of important and recent patents on anti-infective
drug discovery is also included in the journal. The patents
annotated in this section are relevant to the articles published
in this journal issue, categorized by therapeutic areas/targets
and therapeutic agents related to anti-infective drug discovery.
Manuscript Length:
Mini-Reviews: Mini-reviews should be 3000-6000 words
excluding figures, structures, photographs, schemes, tables
etc.
Full-Length Reviews: Full-length reviews
should be 8000-40000 words excluding figures, structures,
photographs, schemes, tables etc.
Research Articles: Research articles should
be 4000-8000 words excluding figures, structures, photographs,
schemes, tables etc.
Drug Clinical Trial Studies: Drug clinical
trial studies are biomedical or health-related interventional
and/or observational research studies conducted in phases
in human beings that follow a pre-defined protocol.The study
is intended to find out whether promising approaches to the
disease prevention, diagnosis, and treatment are safe and
effective. The maximum total page length for a drug clinical
trial study published in the journal is four journal pages.
Each journal page is on average 900 words.
Randomized Drug Clinical Trial Studies: Trial
studies should be 1500 to 3000 words excluding figures, structures,
photographs, schemes, tables etc.
There is no restriction on the number of figures, tables or
additional files e.g. video clips, animation and datasets,
that can be included with each article online. Authors should
include all relevant supporting data with each article (Refer
to Supplementary Material section).
MANUSCRIPT PREPARATION: The manuscript should
be written in English in a clear, direct and active style.
All pages must be numbered sequentially, facilitating in the
reviewing and editing of the manuscript. For further convenience,
the customer support team available at Bentham
Publishing Services (www.benthampublishingservices.com)
can provide assistance to authors for the preparation of manuscripts.
MANUSCRIPT SECTIONS FOR PAPERS:
Manuscripts for review articles submitted to the journal may
be divided into the following sections:
1. Cover Letter: It is mandatory to submit
a signed covering letter along with the manuscript, by the
author to whom correspondence is to be addressed, delineating
the scope of the submitted article declaring the potential
competing interests, acknowledging contributions from authors
and funding agencies, and certifying that the paper is prepared
according to the 'Instructions for Authors'.
All inconsistencies in the text and in the reference section
and any typographical errors must be carefully checked and
corrected before the submission of the manuscript. The article
should not contain any material or information that may be
unlawful, defamatory, fabricated, plagiarized, or which would,
if published, in any way whatsoever, violate the terms and
conditions as laid down in the copyright agreement. The authors
should acknowledge that the publishers have the legal right
to take appropriate action against the authors for any such
violation of the terms and conditions as laid down in the
copy right agreement. To download the cover letter, please
visit: www.benthamscience.com/pri/Covering-Letter.doc
2. Title: The title of the article should
be precise and brief and must not be more than 120 characters.
Authors should avoid the use of non-standard abbreviations.
The title must be written in title case except for articles,
conjunctions and prepositions. Title, running title, byline,
correspondent footnote and keywords should be written as presented
in original manuscript.
3. Short Running Title: Authors must provide
a short ‘running title’ of their manuscript.
4. Authors’ Names and Affiliations:
The names of the authors should be provided according to the
previous citations or as the authors would want them to be
published along with the institutional affiliations, current
address, telephone, cell & fax numbers and the email address.
Email address must be provided with an asterisk in front of
the name of the principal author. The corresponding author
should also be designated and the full address, telephone,
cell & fax numbers and the email address must be stated
to receive correspondence and galley proofs.
5. Abstract: The abstract summarizing the
essential features of the review or research article should
not exceed 250 words, and 150 words for letters and drug clinical
trial studies and must include information regarding patents.
6. Keywords: Authors must provide 6 to 8
keywords in alphabetical order.
7. Text Organization: The main text should
begin on a separate page and should be divided into title
page, abstract and the main text. The text may be subdivided
further according to the areas to be discussed, which should
be followed by the Acknowledgement (if any) and Reference
sections. The Review Article should mention any previous important,
recent and old reviews in the field and contain a comprehensive
discussion starting with the general background of the field.
It should then go on to discuss the salient features of recent
developments along with relevant patents. The authors should
avoid presenting material which has already been published
in a previous review. The authors are advised to present and
discuss their observations in brief. The manuscript style
must be uniform throughout the text and 10pt Times New Roman
fonts should be used. The full term for an abbreviation should
precede its first appearance in the text unless it is a standard
unit of measurement. Italics should be used for Binomial names
of organisms (Genus and Species), for emphasis and for unfamiliar
words or phrases. Non-assimilated words from Latin or other
languages should also be italicized e.g. per se, et al.,
in vitro, in vivo, in situ, etc.
For Research Articles, the manuscript should begin with the
title page and abstract followed by the main text, which must
be structured into separate sections as Introduction, Material
and Methods, Results, Discussion, Conclusion, Current &
Future Developments, Conflict of Interest, Acknowledgements
and References. If your research article reports
the results of a controlled health care intervention such
as a Drug Clinical Trial Studies/Case Report, list your trial
registry, along with the unique identifying number. The patent
registration number and patent authority of the author's intellectual
property must be cited in the article.
Trial registration: There should
be no space between the letters and numbers of your trial
registration number. All drug clinical trial studies, regardless
of when they were completed, and secondary analyses of original
drug clinical trial studies must be registered before submission
of a manuscript based on the trial. Studies designed for other
purposes, such as to study pharmacokinetics or major toxicity
(e.g., phase 1 trials), are exempt. Trial registry
name, registration identification number, and the URL for
the registry should be included at the end of abstract and
also in the space provided on the online manuscript submission
form.
Authors will submit the Trial Protocols along with their manuscript.
The CONSORT (Consolidated Standards of Reporting Trials)
Checklist and Flowchart is also required when submitting
the results of randomized control trials (RCTs).
Ethical Approval of Studies and Informed Consent:
For human or animal experimental investigations, it is
a prerequisite to provide a formal review and approval, or
review and waiver, by an appropriate institutional review
board or ethics committee and should be documented in your
paper. For investigations undertaken on human subjects, state
in the Methods section the manner in which the informed consent
was obtained from the study participants (i.e., oral
or written), where there is an unavoidable risk of breach
of privacy- e.g., in a clinical photograph or in
case details- the patient's written consent or that of the
next of kin, to publication must be obtained. We will ask
you to send a signed consent form before publication. Consent
must be obtained for all Case Reports and Drug Clinical Trial
Studies.
Standard Protocol on Approvals, Registrations,
Patient Consents & Animal Protection:
All clinical investigations must be conducted according
to the Declaration of Helsinki principles. Authors must comply
with the guidelines of the International Committee of Medical
Journal Editors (http://www.icmje.org)
with regard to the patient’s consent for research or
participation in a study. Patients' names, initials, or hospital
numbers must not be mentioned anywhere in the manuscript (including
figures). Editors may request that authors provide documentation
of the formal review and recommendation from the institutional
review board or ethics committee responsible for oversight
of the study.
In addition to the standard patient consent for participation
in research, authors are responsible for obtaining patient
consent-to-disclose forms for all recognizable patients in
photographs, videos, or other information that may be published
in the Journal, in derivative works, or on the journal’s
web site and providing the manuscript to the recognizable
patient for review before submission. The consent-to-disclose
form should indicate specific use (publication in the medical
literature in print and online, with the understanding that
patients and the public will have access) of the patient's
information and any images in figures or videos, and must
contain the patient's signature or that of a legal guardian
along with a statement that the patient or legal guardian
has been offered the opportunity to review the identifying
materials and the accompanying manuscript.
For research involving animals, the authors should indicate
whether the procedures followed were in accordance with the
standards set forth in the Guide for the Care and Use of Laboratory
Animals (published by the National Academy of Science, National
Academy Press, Washington, D.C.).
A specific declaration of such approval and consent-to-disclose
form must be made in the cover letter and in a stand-alone
paragraph at the end of the Methods section especially in
the case of human studies where inclusion of a statement regarding
obtaining the written informed consent from each subject or
subject's guardian is a must. The original should be retained
by the guarantor or corresponding author. Editors may request
to provide the original forms by fax or email.
Patent Review Coverage: Authors should review the
most recent and important patents based on the topic covered.
Coverage of novel bioactive compounds, analogs & targets,
techniques and drug design in all areas of anti-infective
drug discovery should be emphasized, including the significance
of reported patents.
Current & Future Developments:
The review / research article should conclude with a short
section called “Current & Future Developments”.
The author(s) will give their opinion on the current and future
important developments on the topic discussed in their article.
Symbols and Units: Greek symbols and special
characters often undergo formatting changes and get corrupted
or lost during preparation of a manuscript for publication.
To ensure that all special characters used are embedded in
the text, these special characters should be inserted as a
symbol but should not be a result of any format styling (Symbol
font face) otherwise they will be lost during the conversion
to PDF/XML.
Authors are encouraged to consult reporting guidelines. These
guidelines provide a set of recommendations comprising a list
of items relevant to their specific research design.
Only ISO symbols, written in italic, should be used for the
various parameters. All kinds of measurements should be reported
only in International System of Units (SI). SI units should
always be written in Roman and separated from the numerical
value by a space (whatever the language).
The µ in µg or µm should be in Roman. The symbol
for litre is L and that for minute is min. For temperature,
please use only one of °C, &°F or K in the entire
manuscript. As the Angström (1#Å = 10-10
m) is not an SI unit, it should be replaced by the
nanometre (1nm = 10-9 m)
or by the picometer (1pm = 10-12
m): 1# Å = 0.1nm = 100 pm. Multiple units should be
written with negative superscripts (for example, 25mgµL-1
µs-1). The list of notations
should appear just before the first paragraph of full text.
A list of symbols and units should be provided if used extensively
throughout the text.
8. List of Abbreviations: If abbreviations
are used in the text either they should be defined in the
text where first used, or a list of abbreviations can be provided.
9. Acknowledgements: Financial contributions
to the work being reported should be clearly acknowledged.
Please acknowledge anyone (individual/company/institution)
who has contributed to the study by making substantial contributions
to conception, design, acquisition of data, or analysis and
interpretation of data, or who was involved in drafting the
manuscript or revising it critically for important intellectual
content. Please list the source(s) of funding for the study,
for each author, and for the manuscript preparation in the
acknowledgement section.
This journal complies with the International Committee of
Medical Journal Editors' Uniform Requirements for Manuscripts
Submitted to Biomedical Journals www.icmje.org
and the FDA's Good Reprint Practices for the Distribution
of Medical Journal Articles and Medical or Scientific Reference
Publications on Unapproved New Uses of Approved Drugs and
Approved or Cleared Medical Devices www.fda.gov/oc/op/goodreprint.html
10. Conflict of Interest: Any potential
conflict of interest should be clearly acknowledged. No patents
should be cited by authors that are in various stages of legal
litigation.
11. References: References should be numbered
sequentially [in square brackets] in the text and listed in
the same numerical order in the reference section. All references
must be complete and accurate. Online citations should include
the date of access. Journal titles should conform to the present
Index Medicus abbreviations. It is necessary to list all authors
if the total number of authors is 6 or less and for more than
6 authors use 6 authors and then et al. The reference
numbers must be finalized and the bibliography must be fully
formatted before submission.
References should be listed in the following
Vancouver Style:
[1] Journal: Boehm M, Nabel EG.
Angiotensin-converting enzyme 2 - A new cardiac regulator.
N Engl J Med 2002; 347: 1795-7.
[2] Book: Crabtree RH. The Organometallic
Chemistry of the Transition Metals. 3rd
ed. Wiley & Sons: New York 2001.
[3] Book Chapter: Yeh DC, Rocco
T. In: David EG, Armen HT, Ehrin JA, April WA, Eds. Integrative
Cardiovascular Pharmacology. Philadelphia: Lippincott Williams
& Wilkins 2005: 375-83.
[4] Conference Proceedings: Jakeman
DL, Withers SGE. Carbohydrate Bioengineering: Interdisciplinary
Approaches. Proceedings of the 4th
Carbohydrate Bioengineering Meeting. Stockholm, Sweden,
June 10-13, 2001.
[5] Meeting Abstract: Hoffman, BJ.
Metabolism: Amino acid transporters as targets for therapeutic
intervention. American Chemical Society - 228th
National Meeting. Philadelphia, USA (2004).
[6] Website: National Library of
Medicine. Specialized Information Services: Toxicology and
Environmental Health. Available at: http://sis.nlm.nih.gov/Tox/ToxMain.html.
(Accessed on: May 23, 2009).
[7] Thesis: Mackel H. Capturing
the Spectra of Silicon Solar Cells. PhD Thesis, The Australian
National University, Canberra, Australia, December 2004.
[8] Patent: As a service, the Publishers
can provide each author a certain number of relevant patents
to assist them in writing their article. All patent application
references will be provided by the author and will be published
as it is.
Patent Reference Style: All inventors’
names of the cited patents must be stated with the title,
publication number and the year of publication e.g. Chesnut,
J.D., Carrino, J., Leong, L., Madden, K., Gleeson, M.A.G.,
Fan, J., Brasch, M.A., Cheo, D., Hartley, J.L., Byrd, D.R.N.,
Temple, G.F. Methods and compositions for synthesis of nucleic
acid molecules using multiple recognition sites. US7198924
(2007).
Citation of the patents will be according to the international
convention as follows:
• WO Patents: 1978-2003
Masure, H.R., Pearce, B.J., Tuomanen, E. Bacterial
exported proteins and acellular vaccines based thereon. WO9506732
(1995).
Nawaz, A., Lonardo, E.C., Patel, K.J., Lin, S.Y., Matheson,
J., Wearley, L.L. Concomitant oral and topical administration
of anti - infective agents. WO03032985 (2003).
• WO Patents: 2004 onwards
Bearss, D.J., Vankayalapati, H., Xu, Y., Fischetti, V.A.,
Stebbins, C.E. Oxo-imidazolyl compounds having antibacterial
activity. WO2009139870 (2009).
• US Patent Applications: 2001 onwards
Mandeville, W.H., Neenan, T.X., Holmes-Farley, S.R. Ionic
polymers as anti-infective agents. US20010053794 (2001).
Stefanadis, L.G. Stable liquid formulations of anti-infective
agents and adjusted anti-infective agent dosing regimens.
US20090227554 (2009).
.
• Issued/Granted US Patents:
Capps, D. Novel anti infective agents and means of producing
the same. US3758491 (1973).
Klein, L.L., Huang, P.P., Randolph, J.T., Hutchinson, D.K.,
Yeung, M.C., Flentge, C.A. Anti-infective agents. US7517876
(2009).
• EP Patents:
Bright, G.M. Heptanoyl-glu-asp-ala-amino acid immunostimulants.
EP231087 (1992).
Meisel, A., Prass, K., Meisel, C., Halle, E., Dirnagl, U.,
Volk, H.D. Anti-infective agents and/or immunomodulators used
for preventive therapy following an acute cerebrovascular
accident. EP1480646 (2008).
.
Some important points to remember:
• Superscripts in the in-text citations and reference
section should be avoided.
• Abstracts, unpublished data and personal communications
(which can only be included if prior permission has been obtained)
should not be given in the reference section but they may
be mentioned in the text and details provided as footnotes.
• The authors are encouraged to use a recent version
of EndNote (version 5 and above) or Reference Manager (version
10) when formatting their reference list, as this allows references
to be automatically extracted.
12. Tables:
• Data tables should be submitted in
Microsoft Word table format.
• Each table should include a title/caption being explanatory
in itself with respect to the details discussed in the table.
Detailed legends may then follow.
• Table number in bold font i.e. Table 1,
should follow a title. The title should be in small case with
the first letter in caps. A full stop should be placed at
the end of the title.
• Tables should be embedded in the text exactly according
to their appropriate placement in the submitted manuscript.
• Columns and rows of data should be made visibly distinct
by ensuring that the borders of each cell are displayed as
black lines.
• Tables should be numbered in Arabic numerals sequentially
in order of their citation in the body of the text.
• If a reference is cited in both the table and text,
please insert a lettered footnote in the table to refer to
the numbered reference in the text.
• Tabular data provided as additional files can be submitted
as an Excel spreadsheet.
13. Figures/Illustrations: The
quality of the illustrations printed in the journal largely
depends on the quality of the figures/illustration provided
by the author. The acceptance of a manuscript for publication
is subject to the figures being up to the highest standards
in terms of clarity and resolution. In case, the figures supplied
are not up to the standards required, the authors will be
given the option to either return the manuscripts within one
week with appropriate drawings/figures or they may opt to
have these professionally prepared through the paid professional
service available from Bentham Publishing Services.
The authors should provide the illustrations as separate files,
as well as embedded in the text file, numbered consecutively
in the order of their appearance. Each figure should include
a single illustration. Each figure should be closely cropped
to minimize the amount of white space surrounding the illustration.
If a figure consists of separate parts, it is important that
a single composite illustration file be submitted, containing
all parts of the figure.
Photographs should be provided with a scale bar if appropriate,
as well as high-resolution component files.
Scaling/Resolution:
For Line Art image type, which is generally an image based
on lines and text and does not contain tonal or shaded areas,
the preferred file format is TIFF or EPS, with color mode
being Monochrome 1-bit or RGB, in a resolution of 900-1200
dpi.
For Halftone image type, which is generally a continuous tone
photograph and contains no text, the preferred file format
is TIFF, with color mode being or RGB or Grayscale, in a resolution
of 300 dpi.
For Combination image type, which is generally an image containing
halftone in addition to text or line art elements, the preferred
file format is TIFF, with colour mode being or RGB or Grayscale,
in a resolution of 500-900 dpi.
Formats:
For illustrations, the following file formats are acceptable:
• Illustrator
• EPS (preferred format for diagrams)
• PDF (also especially suitable for diagrams)
• PNG (preferred format for photos or images)
• Microsoft Word (version 5 and above; figures must
be a single page)
• PowerPoint (figures must be a single page)
• TIFF
• JPEG (conversion should be done using the original
file)
• BMP
• CDX (ChemDraw)
• TGF (ISISDraw)
Bentham Science does not process figures submitted
in GIF format.
If the large size of TIFF or EPS figures acts as an obstacle
to online submission, authors may find that conversion to
JPEG format before submission results in significantly reduced
file size and upload time, while retaining acceptable quality.
JPEG is a 'lossy' format, however in order to maintain acceptable
image quality, it is recommended that JPEG files are saved
at high or maximum quality.
Files should not be compressed with tools such as Zipit or
Stuffit prior to submission as these tools will in any case
produce negligible file-size savings for JPEGs and TIFFs,
which are already compressed.
Please do not:
1. Supply embedded graphics in your word processor (spreadsheet,
presentation) document;
2. Supply files that are optimized for screen use (like GIF,
BMP, PICT, WPG); the resolution is too low;
3. Supply files that are too low in resolution;
4. Submit graphics that are disproportionately large for the
content.
Image Conversion Tools:
There are many software packages, many of them freeware or
shareware, capable of converting to and from different graphics
formats, including PNG.
Good general tools for image conversion include GraphicConverter
on the Macintosh, PaintShop Pro, for Windows, and ImageMagick,
which is available on Macintosh, Windows and UNIX platforms.
Note that bitmap images (e.g. screenshots) should not be converted
to EPS, since this will result in a much larger file size
than the equivalent JPEG, TIFF, PNG or BMP, with no increase
in quality. EPS should only be used for images produced by
vector-drawing applications such as Adobe Illustrator or CorelDraw.
Most vector-drawing applications can be saved in, or exported
as, EPS format. In case the images have been originally prepared
in an Office application, such as Word or PowerPoint, then
the original Office files should be directly uploaded to the
site, instead of being converted to JPEG or another format
that may be of low quality.
Color Figures/Illustrations:
• The cost for the first published page of color figures
is US$ 965; the second additional page will
be for US$ 705 and each subsequent page for
US$ 480.
Color figures publication in the reprints:
Reprints of pages containing colored illustrations will be
charged at US$ 186 for each color page per
100 reprints.
• Color figures should be supplied in CMYK not RGB colors.
14. Chemical Structures: Chemical structures
MUST be prepared in ChemDraw (CDX) and provided as separate
file.
Structure Drawing Preferences:
[As according to the ACS style sheet]
Drawing Settings:
Chain angle 120°
Bond spacing 18% of width
Fixed length 14.4
pt (0.500cm, 0.2in)
Bold width
2.0 pt (0.071cm, 0.0278in)
Line width 0.6
pt (0.021cm, 0.0084in)
Margin width 1.6 pt
(0.096cm)
Hash spacing 2.5 pt (0.088cm, 0.0347in)
Text settings:
Font
Times New Roman
Size
8 pt
Under the Preference Choose:
Units
points
Tolerances 3
pixels
Under Page Setup Use:
Paper
US letter
Scale
100%
15. Supportive/Supplementary Material:
We do encourage to append supportive material, for
example a PowerPoint file containing a talk about the study,
a PowerPoint file containing additional screenshots, a Word,
RTF, or PDF document showing the original instrument(s) used,
a video, or the original data (SAS/SPSS files, Excel files,
Access Db files etc.) provided it is inevitable or endorsed
by the journal's Editor.
Supportive/Supplementary material intended for publication
must be numbered and referred to in the manuscript but
should not be a part of the submitted paper. In-text
citations as well as a section with the heading "Supportive/Supplementary
Material" before the "References" section should
be provided. Here, list all Supportive/Supplementary Material
and include a brief caption line for each file describing
its contents.
Any additional files will be linked into the final published
article in the form supplied by the author, but will not be
displayed within the paper. They will be made available in
exactly the same form as originally provided only
on our website. Please also make sure that each additional
file is a single table, figure or movie (please do not upload
linked worksheets or PDF files larger than one sheet). Supportive/
Supplementary material must be provided in a single zipped
file not larger than 4 MB.
Authors must clearly indicate if these files are not for publication
but meant for the reviewers'/editors' perusal only.
PERMISSION FOR REPRODUCTION: Published/reproduced
material should not be included unless you have obtained written
permission from the copyright holder, which should be forwarded
to the Editorial Office in case of acceptance of your article
for publication.
For obtaining permission of reproducing any material
published in an article by Bentham Science Publishers,
please fill in the request FORM
and send to patents@benthamscience.org
for consideration.
REVIEWING AND PROMPTNESS OF PUBLICATION: All papers submitted for publication are immediately subjected to editorial scrutiny, usually in consultation with members of the journal Editorial Advisory Board and outside independent reviewers. Every effort will be made to peer review submitted papers quickly. Papers which are delayed by authors in revision for more than 30 days will have to be re-submitted as a new submission. Papers accepted for publication are typeset and proofs are dispatched to authors for any corrections prior to final publication.
PAGE CHARGES: No page charges will be levied
to the authors.
LANGUAGE EDITING: Manuscripts submitted containing
many English typographical errors will not be published. Authors
from non-English language countries are advised to use the
services of our professional language editing department prior
to submitting their manuscript to the journal. Please contact
Bentham Publishing Services (www.benthampublishingservices.com)
for a language editing quote via e-mail at: info@benthampublishingservices.com
stating the total number of words of the article to be edited.
PROOFS: Authors will receive page proofs
of their accepted paper before publications. To avoid delays
in publication, proofs should be checked immediately for typographical
errors and returned within 48 hours. Major changes are not
acceptable at the proof stage. If unable to send corrections
within 48 hours due to some reason, the author(s) must at
least send an acknowledgement on receiving the galley proofs
or the article will be published exactly as received and the
publishers will not be responsible for any error occurring
in the published manuscript in this regard.
The corresponding author will be solely responsible for ensuring
that the revised version of the manuscript incorporating all
the submitted corrections receives the approval of all the
co-authors of the manuscript.
REPRINTS: Each first-named (corresponding)
author will receive electronically five free reprints of their
published article. Printed reprints may be ordered from the
Publisher prior to publication of the article. First named
authors may also order a personal print and online subscription
of the journal at 50% off the normal subscription rate by
contacting the subscription department at e-mail: subscriptions@benthamscience.org
OPEN ACCESS PLUS: Accepted articles can be published online for free open access for all to view. Open access publishing provides the maximum dissemination of the article to the largest audience. Authors must pay for this service. All corresponding authors will be asked to indicate whether or not they wish to pay to have their paper made freely available on publication. If authors do not select the Open Access option, then their article will be published with standard subscription-based access at no charge.
Bentham Science offers authors the choice of open access publication of their articles at a fee of US$ 2,200 per published article which allows indefinite free-to-view online publication with Bentham Science.
For more information please contact us at e-mail: openaccess@benthamscience.org
COPYRIGHT: Authors who publish in Bentham
Science Journals will transfer copyright to their work
to Bentham Science Publishers. Submission of a manuscript
to the respective journals implies that all authors have read
and agreed to the content of the Covering Letter or the Terms
and Conditions. It is a condition of publication that manuscripts
submitted to this journal have not been published and will
not be simultaneously submitted or published elsewhere. Plagiarism
is strictly forbidden, and by submitting the article for publication
the authors agree that the publishers have the legal right
to take appropriate action against the authors, if plagiarism
or fabricated information is discovered. By submitting a manuscript
the authors agree that the copyright of their article is transferred
to the publishers if and when the article is accepted for
publication. Once submitted to the journal, the author will
not withdraw their manuscript at any stage prior to publication.
PLAGIARISM PREVENTION: Bentham Science Publisher uses the iThenticate software to detect instances of overlapping and similar text in submitted manuscripts. iThenticate software checks content uploaded by a journal editorial office against a database of periodicals, the Internet, and a comprehensive article database. It generates a similarity report, including the percentage overlap between the uploaded article and published material. Any instances of content overlap are treated according to a journal's peer review integrity statement and the policies recommended by the editorial Committee. You are assured that the publisher, where you are submitting your manuscript, is committed to actively combating plagiarism and publishing original research.
E-PUB AHEAD OF SCHEDULE: Bentham Science
Publishers are pleased to offer electronic publication of
accepted papers prior to scheduled publication. These peer-reviewed
papers can be cited using the date of access and the unique
DOI number. Any final changes in manuscripts will be made
at the time of print publication and will be reflected in
the final electronic version of the issue. Articles ahead
of schedule may be ordered by pay-per-view at the relevant
links by each article stated via the E-Pub
Ahead of Schedule (http://www.benthamscience.com/pri/E-Pub-Ahead-of-Schedule.htm).
Disclaimer: Articles appearing in E-Pub Ahead-of-Schedule
sections have been peer-reviewed and accepted for publication
in this journal and posted online before scheduled publication.
Articles appearing here may contain statements, opinions,
and information that have errors in facts, figures, or interpretation.
Accordingly, Bentham Science Publishers, the editors
and authors and their respective employees are not responsible
or liable for the use of any such inaccurate or misleading
data, opinion or information contained of articles in the
E-Pub Ahead-of-Schedule. |
